drug developmentBusinessTrump’s FDA Cuts Are Putting Drug Development at RiskBy Caroline HaskinsBusinessGoogle DeepMind’s Groundbreaking AI for Protein Structure Can Now Model DNABy Will KnightThe Big StoryYou Know It’s a Placebo. So Why Does It Still Work?By Tom VanderbiltScienceThe FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic RivalBy Emily MullinScienceEveryone Was Wrong About AntipsychoticsBy Max G. LevyScienceThe First Pill for Postpartum Depression Is Almost HereBy Emily MullinScienceA Patient May Be Free of HIV, Thanks to This DrugBy Emily MullinScienceA Critical New Drug Is Coming—Unless Agriculture Gets There FirstBy Maryn McKennaScienceA Crucial Group of Covid Drugs Has Stopped WorkingBy Emily MullinScienceScientists Grew Mini Human Guts Inside MiceBy Emily MullinScienceThese Nanobots Can Swim Around a Wound and Kill BacteriaBy Max G. LevyScienceTo Test Cancer Drugs, These Scientists Grew ‘Avatars’ of TumorsBy Max G. LevyBiotechAn AI Finds Superbug-Killing Potential in Human ProteinsBy Max G. LevyScienceNew Covid Drugs Are Here—and They Could Change the PandemicBy Adam RogersIdeasLet’s Get Real About the President’s Antibody TreatmentBy Hilda BastianIdeasScientists May Be Using the Wrong Cells to Study Covid-19By Roxanne KhamsiScienceSupercomputers Are Stocking Next Generation Drug PipelinesBy Megan MolteniBusinessDrug Prices Are Too Damn High. Here's How to Fix ThemBy David WolmanScienceCan Antibiotics User Fees Force Down Drug Mis-Use and Overuse?By Maryn McKennaScienceMore on 'Nightmare Bacteria': Maybe Even Worse Than We Thought?By Maryn McKennaScienceDrug-Resistant Gonorrhea: WHO Agrees It's An EmergencyBy Maryn McKennaScienceDrug-Resistant Gonorrhea: How We Lost TrackBy Maryn McKennaScienceGoodbye, Magic Bullet: Hello, Highly Resistant GonorrheaBy Maryn McKennaScienceNot Enough Antibiotics: Just an Incentives Problem?By Maryn McKennaMore Stories
.jpg)
